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chemotherapy had lower distant and abdominal relapse rates, 
and significantly better DFS versus those who received six cycles 
of chemotherapy and no adjuvant RT. Post-operative RT should 
be considered in the treatment regimen for this patient group.  
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Purpose: Most women with cervical cancer in Sub-Saharan Africa 
present with locally advanced disease. These women require 
external beam radiotherapy (EBRT) and brachytherapy for a 
curative treatment course. Data on the outcomes of these 
patients remain sparse. We report the experience of The 
National Centre for Radiotherapy and Nuclear Medicine in Accra, 
Ghana. 
Methods and Materials: The charts of patients treated from 
2006-2011 were reviewed. Patients treated without 
brachytherapy or with palliative intent were excluded. Staging 
CT scans were not routinely performed. Cobalt-60 EBRT was 
followed by one or two low-dose-rate brachytherapy insertions. 
Concurrent weekly cisplatin was recommended. Because many 
patients experienced delays from diagnosis to treatment, we 
calculated rates of locoregional recurrence (LRR), and distant 
recurrence (DR) from the date of the last radiation treatment to 
the event date, or last follow up, when no event recurred, using 
a competing risk approach. Overall survival was calculated from 
the date of diagnosis using the Kaplan-Meier method. 
Results: Two hundred and fifty-four patients had a median age 
at diagnosis of 55 years. FIGO stage was IB in 7% of patients, IIA 
in 13%, IIB in 43%, IIIA in 8%, IIIB in 25% (48% had sidewall 
involvement, 33% hydronephrosis, and 18% both), and IVA in 4%. 
Median dose to point A was 83 Gy (range 56-98 Gy) with a median 
contributing EBRT and brachytherapy dose of 46 Gy (range: 32-
52 Gy) and 29 Gy (range: 8-50 Gy), respectively. EBRT boosts to 
the sidewall or primary tumour were used in 12% of patients with 
a mean dose of 9 Gy (range: 4-20 Gy). Median doses to the ICRU 
bladder and rectal points were 71 Gy and 65 Gy. Sixty-four 
percent of patients received concurrent cisplatin. The median 
number of cycles was four, with 89% and 39% of patients 
receiving at least three and five cycles, respectively. Median 
overall treatment time was 73 days (range: 27-329 days). Median 
follow up was 2.5 years with many patients lost to follow up. 
Three-year OS, LRR, and DR were 87%, 20%, and 11%, 
respectively. The most commonly reported late side-effect was 
vaginal stenosis/shortening in 32% of patients. We also identified 
nearly 300 patients who were offered curative treatment but 
never returned to start; they will be the subjects of a subsequent 
study on barriers of care. 
Conclusions: We report the largest single institution series of 
cervical cancer patients treated with definitive EBRT and 
brachytherapy in Sub-Saharan Africa. Despite advanced stage at 
presentation, preliminary data is promising. However, many 
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Background: Close resection margins (CM) and lymph node 
involvement with extracapsular extension (ECE) are associated 
with poor clinical outcome of patients with squamous cell head 
and neck cancer (SCCHNC) after surgical resection and adjuvant 
chemoradiation. We performed in this subset of patients an open 
label Phase 2 trial and investigated the effect of additional 
cetuximab administered concomitantly and as maintenance 
therapy during and after adjuvant radiochemotherapy. 
Methods and Materials: Surgically treated SCCHNC with CM or 
ECE were eligible for the study. 61.6 Gy (1.8/2.0/2.2 Gy, d1-36) 
were administered using an integrated boost IMRT-technique. 
Cisplatin (20 mg/m2, d1-5 and d29-33) and 5-FU (continuous 
infusion: 600 mg/m2, d1-d5 + d29-33) were given concurrently. 
Cetuximab started seven days prior to radiochemotherapy at 400 
mg/m2 followed by weekly doses of 250 mg/m2. Maintenance 
cetuximab began after radiochemotherapy at 500 mg/m² every 
two weeks for six months. The study was conducted at 10 
investigational sites recruiting in Germany from May 2008 until 
December 2010.  
Results: The number of patients enrolled was 83. Five patients 
did not meet inclusion criteria leaving 78 for analysis. Median 
follow up of was1.5 years. Eighteen patients had events (death 
of progression) of which 10 were locoregional relapses. Two-year 
overall survival, disease-free survival, and locoregional tumour 
control were 86% (95%CL 79-95%), 77% (95% CL 66-86%), and 82% 
(95%CL 93-78%). Acute toxicity was in the expected range 
(separate abstract). Two thirds of patients started maintenance 
cetuximab after completion of chemoradiation and on third 
completed all treatment as scheduled. 
Conclusions: Adjuvant radiochemotherapy with concomitant and 
maintenance cetuximab is feasible and results in a favourable 
clinical outcome in high-risk SCCHNC after surgical resection 
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Purpose: The causal relationship between cancer of the cervix 
uteri and infection with human papillomavirus (HPV) has been 
adequately studied. There are also indications that there is a link 
between HPV infection and squamous cell carcinoma of the head 
and neck. The aim of this study was to find out the incidence and 
clinical outcome of HPV infection in head neck cancer patients 
in a German population. 
Methods and Materials: In a retrospective study, the tumour 
tissue from 164 patients (110 men, 54 women, 62.8 years + 12.7) 
with head neck cancer (oropharynx = 65 nasopharynx = 10, larynx 
= 13, hypopharynx = 15, oral cavity = 33 CUP = five, Other = 23) 
were tested for HPV infection and the clinical outcome was 
investigated. p16 as a surrogate marker for HPV infection was 
determined. Moreover, risk factors such as nicotine, alcohol 
abuse, resection margin of the tumour tissue, histology, lymph 
nodes involvement, extracapsular spread, tumour stage, and the 
treatment of the tumour were analyzed for local control and 
overall survival. 
Results: The incidence of HPV infection in oropharynx-carcinoma 
patients was 33%. Patients with HPV-positive oropharyngeal 
carcinomas showed a tendency towards longer survival time, (p 
= 0.76, HR: 2.42, 95% CI 0.91 - 6.44) compared to HPV-negative 
tumours. All other parameters were except the tumour stage in 
the uni and multivariate analysis not significant for local control 
and overall survival. The reason for this might be the small 
number of cases in our individual subgroups 
